Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Interagency Patent Coordination and Improvement Act of 2023
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Biologics Competition Act of 2023
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC via COVINGTON & BURLING LLP
2023 · first_quarter · Q1
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Filing targets: Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Preserve Access to Affordable Generics and Biosimilars Act
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Stop STALLING Act
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Affordable Prescriptions for Patients Act of 2023
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
TRACK Act of 2023
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Maintaining Investments in New Innovation Act
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Increasing Prescription Drug Competition Act
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Interagency Patent Coordination and Improvement Act of 2023
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Increasing Transparency in Generic Drug Applications Act
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Ensuring Timely Access to Generics Act of 2021
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · Firm: COVINGTON & BURLING LLP
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).